NDAORALCAPSULEPriority Review
Approved
Oct 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
DEMSER (metyrosine) by Bausch + Lomb is catecholamine synthesis inhibitors [moa]. Approved for catecholamine synthesis inhibitor [epc]. First approved in 1979.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEMSER (metyrosine) is an oral catecholamine synthesis inhibitor approved in 1979 for pheochromocytoma and psychosis. It works by inhibiting tyrosine hydroxylase, the first enzyme in catecholamine biosynthesis, thereby reducing epinephrine and norepinephrine production. The drug addresses severe hypertension and symptoms associated with catecholamine excess in rare endocrine tumors.
$0.321MPart D
LOE ApproachingDeclining
Minimal commercial opportunity; product is nearing loss of exclusivity with extremely low claim volume, indicating either market maturation or limited patient population awareness.
Mechanism of Action
Catecholamine Synthesis Inhibitors
Pharmacologic Class:
Catecholamine Synthesis Inhibitor
Indications (1)
Clinical Trials (1)
Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
Started Jun 2010
2 enrolled
Velo-cardio-facial SyndromePsychosis
Career Relevance
DEMSER offers limited career mobility and growth trajectory; roles are confined to niche rare disease specialists, medical affairs for pheochromocytoma centers, and regulatory compliance. Working on DEMSER suits early-career medical or commercial professionals seeking rare disease expertise or late-stage product management experience.
Worked on DEMSER at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.